BUSINESS● LOW1h ago · Oct 6, 2026, 2:02 PM
ArriVent plunges as lead asset fails in late-stage cancer trial
Seeking Alpha Tech · global
ArriVent's stock has plunged following the failure of its primary drug candidate in a late-stage cancer trial. This event significantly impacts the company's market value and its therapeutic development pipeline.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS19m agoU.S. stocks close gap with ex-U.S. marketsSeeking Alpha TechBUSINESS21m agoAnduril to invest $3.7B in new Baltimore shipyard to build Virginia-class submarine partsThe Hill